Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,894 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于公司获得药品注册证书的公告
Regulatory Filings Classification · 85% confidence The document is a formal announcement by TianShiLi Pharmaceutical Group Co., Ltd. regarding receipt of a drug registration certificate from the National Medical Products Administration. It contains no financial statements, management changes, dividends, or investor presentation material. Instead, it is a routine regulatory announcement required by the exchange/regulators. There is no detailed financial report or notice of a meeting/event; thus it does not fit any specialized category such as 10-K, IR, ER, or M&A. It best fits into the generic Regulatory Filings category (RNS).
2026-06-08 Chinese
天士力关于2026年度董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 94% confidence The document is an official announcement by the board of TianShiLi Pharmaceutical Group outlining the 2026 compensation scheme for directors and senior management, including fixed allowances, performance pay, and long-term incentives. It does not report financial results, nor is it a change in board/management composition. It specifically details remuneration structure, fitting the definition of Remuneration Information (DEF 14A).
2026-06-08 Chinese
天士力关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice convening the company’s 2026 first extraordinary general meeting, detailing date, location, voting procedures, agenda items, and proxy authorization form. It is clearly materials sent to shareholders to provide information on forthcoming meeting and solicit their votes, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-08 Chinese
天士力医药集团股份有限公司薪酬管理制度
Remuneration Information Classification · 90% confidence The document is the company’s internal Remuneration Management System, detailing the principles, structures, committees, and rules for board and senior management compensation. It focuses exclusively on executive and director pay policies and mechanisms. This matches the definition of Remuneration Information (Code: DEF 14A).
2026-06-08 Chinese
天士力第九届董事会第22次会议决议公告
Regulatory Filings Classification · 78% confidence The document is an announcement of the board of directors’ meeting resolutions (board meeting notice, attendance, and voting results on a series of compensation and governance proposals). It does not contain financial statements (excluding IR or 10-K), is not a shareholder vote announcement (DVA), not an earnings release, not an AGM presentation, and does not announce any change in directors or senior management. It therefore falls into the general regulatory announcements category: Regulatory Filings (RNS).
2026-06-08 Chinese
天士力关于召开2025年年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 46% confidence The document is an announcement by Tasly Pharmaceutical (600535) scheduling a 2025 Annual and Q1 2026 performance briefing (业绩说明会), providing timing, location, participation instructions, and company contacts. It is not the full financial report, not an earnings release of results, nor the transcript or slides—it simply notifies investors of an upcoming earnings explanation meeting. This type of notice does not correspond to any specialized category (e.g., 10-K, IR, ER, IP) and therefore falls into the fallback “Regulatory Filings” category.
2026-05-18 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.